BIO

BIO-RAD LABORATORIES INC

Healthcare • USA

Apr 05 • 04:00PM ET
248.67
+5.48 (+2.25%)
Company Profile

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactur ... read more

Full Time Employees 7,700
Phone 510 724 7000
Website https://www.bio-rad.com
CEO Mr. Norman D. Schwartz
IPO Date 1980-02-27
Sector Healthcare
Industry Medical - Devices
Address 1000 Alfred Nobel Drive, Hercules, CA 94547
Balance Sheet
Total Cash $521,400,000
Total Debt $1,369,500,000
Current Ratio 5.99
Quick Ratio 4.12
Profitability
Gross Margin 53.48%
Net Margin -85.17%
ROE -32.40%
ROA -22.72%
ROIC 2.42%
Balance Sheet
Total Cash $521,400,000
Total Debt $1,369,500,000
Current Ratio 5.99
Quick Ratio 4.12
Profitability
Gross Margin 53.48%
Net Margin -85.17%
ROE -32.40%
ROA -22.72%
ROIC 2.42%
Name BIO-RAD LABORATORIES INC Sector Healthcare Currency USD Relative Volume 2.52 Market Cap 6319
Current Ratio 6.48 Dividend / Share 0.0 EPS -65.36 Revenue 2566500000 P/S 2.5
P/E -3.4 Beta 0.82 Income -1844200000 Volume 766846 Average Volume 303894
Distance to 200DMA -28.72% 200 DMA 316.48 50 DMA 283.52 ROA -17.5 ROE -24.7
Distance to 50DMA -20.43% Return 1Y -31.26% Return YTD -31.33% Forward PE Qtly Growth YOY
Debt/Eq 0.42 P/B 1.0 Dividend Yield 0.0% Net Margin -71.86% Payout Ratio 0.0
Performance
52 Week Range 0.0%
Distance to 200DMA 0.0%
Day Change Percent $0.00

Performance Range

Day

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Balance Sheet
Total Cash $410,377,000
Total Debt $1,388,077,000
Current Ratio 6.14%
Quick Ratio 1.75%
Profitability
Gross Margin 53.48%
Net Margin -85.17%
ROE -32.40%
ROA -22.72%
ROIC 2.42%
Valuation
Price to Earnings -3.21
Price to Book 1.04
Price to Sales 2.73
Price to Free Cash Flow 19.54
Dividends
Payout Ratio -0.00%
Dividend Yield 0.00%
Dividend Amount $0.00
Performance
52 Week Range 0.0%
Distance to 200DMA 0.0%
Day Change Percent $0.00
Company Profile

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactur ... read more

Full Time Employees 7,700
Phone 510 724 7000
Website https://www.bio-rad.com
CEO Mr. Norman D. Schwartz
IPO Date 1980-02-27
Sector Healthcare
Address 1000 Alfred Nobel Drive, Hercules, CA 94547
Histogram - Daily

Balance Sheet
Total Cash $410,377,000
Total Debt $1,388,077,000
Current Ratio 6.14%
Quick Ratio 1.75%
Profitability
Gross Margin 0.5440%
Net Margin -0.3020%
ROE -0.10%
ROA -0.07%
Company Profile

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactur ... read more

Full Time Employees 7,700
Phone 510 724 7000
Website https://www.bio-rad.com
CEO Mr. Norman D. Schwartz
IPO Date 1980-02-27
Sector Healthcare
Address 1000 Alfred Nobel Drive, Hercules, CA 94547
Monthly Win Rate

Balance Sheet (Multi-Column Example)
Dec 2024 Sep 2024 Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023
Cash & Short Term Investments 53,775.0 65,171.0 61,801.0 67,150.0 73,100.0 61,555.0 62,482.0 55,872.0
Receivables 59,306.0 66,243.0 43,172.0 41,150.0 50,102.0 60,985.0 39,186.0 35,899.0
Inventory 6,911.0 7,286.0 6,165.0 6,232.0 6,511.0 6,331.0 7,351.0 7,482.0

Latest News

BIO-key Reports Q1'25 Revenue of $1.6M and Improved Cash Position of $3.1M; Hosts Investor Call Tomorrow, Friday May 16th at 10am ET
BIO-key Reports Q1'25 Revenue of $1.6M and Improved Cash Position of $3.1M; Host

HOLMDEL, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- BIO-key ® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) solutions featuring

2025-05-15 16:15:00 - globenewswire.com
Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference
Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Mar

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Executiv

2025-05-12 16:30:00 - businesswire.com
BIO-key, Provider of Identity and Access Management Solutions Enhanced with Biometric Authentication Hosts Q1 Investor Call Fri. May 16th at 10am ET
BIO-key, Provider of Identity and Access Management Solutions Enhanced with Biom

BKYI: BIO-key, Provider of Identity and Access Management Solutions Enhanced with Biometric Authentication Hosts Q1 Investor Call Fri. May 16th at 10am ET.

2025-05-09 11:00:00 - globenewswire.com
BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM
BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM

MINNEAPOLIS , May 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2

2025-05-07 06:30:00 - prnewswire.com
BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS
BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS

MINNEAPOLIS , May 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2025. Third Quarter FY2025 Highlights Third

2025-05-07 06:30:00 - prnewswire.com
KRONOS BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kronos Bio, Inc. - KRON
KRONOS BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swic

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of

2025-05-04 12:11:00 - businesswire.com
BIO Beats on Q1 Earnings, Lowers '25 View, Stock Up in Aftermarket
BIO Beats on Q1 Earnings, Lowers '25 View, Stock Up in Aftermarket

Bio-Rad witnesses first-quarter top-line decline in its Life Science segment, primarily due to challenges in the academic research market.

2025-05-02 09:00:41 - zacks.com
Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates
Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.54 per share, beating the Zacks Consensus Estimate of $1.73 per share. This compares to earnings of $2.29 per share a year ago.

2025-05-01 18:40:36 - zacks.com
Bio-Rad Reports First-Quarter 2025 Financial Results
Bio-Rad Reports First-Quarter 2025 Financial Results

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t

2025-05-01 16:15:00 - businesswire.com
BIO-key Regains Compliance with Nasdaq Listing Rules After Receiving Notice of Non-Compliance
BIO-key Regains Compliance with Nasdaq Listing Rules After Receiving Notice of N

HOLMDEL, N.J. , April 24, 2025 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) solutions featurin

2025-04-24 16:30:00 - globenewswire.com
Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: Wh

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2025-04-24 11:07:50 - zacks.com
Should You Continue to Hold Bio-Rad Stock in Your Portfolio?
Should You Continue to Hold Bio-Rad Stock in Your Portfolio?

BIO continues to attract investors' attention due to its robust performance in the ddPCR platform.

2025-04-03 10:00:48 - zacks.com
BIO-key Trims 2024 Net Loss 49% to $4.3M, Reflecting Higher Gross Margin and Lower Operating Costs, Offsetting 11% Revenue Decrease Due to Business Transition; Hosts Investor Call Today at 10am ET
BIO-key Trims 2024 Net Loss 49% to $4.3M, Reflecting Higher Gross Margin and Low

BIO-key Trims 2024 Net Loss 49% to $4.3M, Reflecting Higher Gross Margin & Lower Operating Costs, Offsetting 11% Revenue Decrease From Business Transition.

2025-03-27 07:58:00 - globenewswire.com
BIO-key Completes Initial Biometric-Based Identity and Access Management Deployment for New International Defense Agency Customer in Record Time
BIO-key Completes Initial Biometric-Based Identity and Access Management Deploym

BIO-key (BKYI) Completes Initial Biometric-Based Identity and Access Management Deployment for New International Defense Agency Customer in Record Time.

2025-03-26 07:58:00 - globenewswire.com
Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts
Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts

IRVINE, Calif., March 24, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its fourth q

2025-03-24 16:05:34 - prismmediawire.com